Share on Facebook
Share on Twitter
Share on LinkedIn

The U.S. Supreme Court left intact a $142 million award against Pfizer Inc. (PFE) and let two similar suits go forward with claims that the drugmaker defrauded insurers by illegally marketing its Neurontin epilepsy drug.

The justices without comment today rejected Pfizer’s appeal, letting stand three connected federal appeals court decisions. The cases are part of the fallout from a 2004 guilty plea by Pfizer’s Warner-Lambert unit to charges that it promoted Neurontin for unapproved “off-label’” uses.

Click here to read more.